https://www.selleckchem.com/pr....oducts/ldc195943-imt
H3.3 G34-mutant diffuse hemispheric gliomas have been proposed as a new entity separate from IDH-wildtype glioblastoma. These changes increase diagnostic accuracy and refine clinical care by changing treatment recommendations, for example for patients with IDH-wildtype astrocytomas showing molecular features of glioblastoma. They also have major implications for clinical trial design. These changes increase diagnostic accuracy and refine clinical care by changing treatment recommendations, for example for patients with IDH-wildty
Like
Comment
Share
